【摘要】 目的:探讨度洛西汀在慢性酒依赖伴抑郁患者中的临床疗效及安全性。方法:将符合条件的66例慢性酒依赖伴抑郁患者随机分成两组,分别给予度洛西汀联合常规戒酒治疗(研究组)和常规戒酒治疗(对照组),进行8周的系统治疗,使用HAMD(汉密尔顿抑郁量表),HAMA(汉密尔顿焦虑量表),CGI(临床疗效总体评估量表),饮酒渴求度评估其疗效;以TESS(副反应量表)和有关的实验室检查评定药物副反应。结果:治疗以后,研究组与对照组相比较,研究组第1、2、4、8周HAMD-17、HAMA、CGI评分明显下降(P<0.05或P<0.01);与对照组相比,研究组第1、2、4、8周的饮酒渴求度明显降低(P<0.05或P<0.01)。结论:度洛西汀治疗酒依赖伴抑郁安全有效,并能明显降低酒依赖患者的心理渴求。更多还原

【Abstract】 Objective: To explore the efficacy and safety of Duloxetine in treating alcohol abuse patients with depression. Methods:66 alcohol abuse patients with depression were randomly divided into Duloxetine group( n = 33) and Controll group( n = 33). Duloxetine group was treated by Duloxetine combined with regular treatment of alcohol abuse. Controll group was treated by regular treatment of alcohol abuse only. They were treated for 8 weeks. The efficacy and safety were evaluated at the baseline and at the end of week 1,2,4,8 respectively. Results: At the end of the study,The Duloxetine group was significantly improved. The scales of HAMD /HAMA decreased significantly at the end of week 1,2,4,8 in Duloxetine group( P < 0. 05). The Duloxetine group was significantly lowered down the patients alcohol craving. Conclusion: Duloxetine is a safe and effective drug in the treatment of alcohol abuse patients with depression.更多还原